The SnapChipTM is more than a simple multiplex, it’s multiple singleplex!
Based in Montréal (Canada), Parallex Bioassays is an innovative biotech company developing antibody microarrays for the biomedical and food industries. Thanks to a new patented technology called the SnapChipTM, we eliminate the cross-reaction inherent to multiplexed immunoassays and thereby open the door to new opportunities. Now, physically isolated micro-assays can be combined in a single and highly customizable chip without any compromise on the quality of the results. Also, measurements of post-translational modifications, protein isoform and binding partners can be included to create a unique multiparametric Chip.
Our mission is to offer innovative and customizable solutions to accelerate academic and industrial research.
Sebastien Bergeron, Ph.D.
Chief Executive Officer
Sebastien Bergeron is the founder and CEO of Parallex BioAssays. He completed a Ph.D. in physiology and endocrinology, with a focus on type II diabetes. As a postdoctoral fellow with Pr. David Juncker in the Biomedical Engineering department at McGill University, he developed a strong interest in microfluidics and immunoassay miniaturization. He drove the development of a new microarray format, called the SnapChip. This cross-reaction-free platform offers high quality results while permitting rapid, flexible and customized multiplexed immunoassay development. In 2015, Sebastien founded Parallex BioAssays to make this technology available to the scientific community.
François Paquet-Mercier, Ph.D.
François Paquet-Mercier completed his Ph.D. in chemistry at Laval University where he specialized in development of vibrational spectroscopy and microscopy techniques to study biopolymers and biofilms. One of its main motivation is to find new and innovative solutions to help the scientific community in its effort to find new treatments for major diseases. The excellence of his academic and research achievements was recognized by master and doctoral postgraduate scholarships from FRQNT and NSERC. He joined Parallex BioAssays in 2019, and oversees the development, optimization and validation of multiplex immunoassays. He will lead, direct and coordinate the research and development field. As well as implementing new directives.
Louisa Guignard, M.sc.
Louisa Guignard completed her master’s degree in sciences and management of biotechnologies – Biomarkers and in vitro diagnostics, at Grenoble-Alpes University, in France. In 2019, she decided to start an internship with ParallexBioAssays in the research and development department. After the end of her internship, Louisa became an associate scientist and is now working on the development, optimization, and validation of multiplex immunoassays under the lead of M. Paquet-Mercier. The data acquired through research are analyzed by Louisa and will accordingly, implement strategies and interpret findings.
Ya Ning Zhao, B.s.c
Business Development Specialist
Ya Ning Zhao completed her bachelor’s degree in pharmacology at Sherbrooke University. Before joining Parallex Bioassay, in 2019, she worked in the biotherapeutic industry as a Quality control specialist. Having already experienced the scientific field, a change was due, and she made the big jump in the marketing territory with Parallex. As a student, she took some pharmaceutical marketing courses as well as entrepreneurship in the pharmaceutical industry course. Having a background in these two fields made her capable of handling diverse tasks for this position, from creating multiple marketing tools to analyzing different data in order to optimize sales to contacting potential clients.
Advisory Board Chair at Parallex BioAssays
President & CEO at MRM Proteomics Inc.
Claude LeDuc is a professional Executive CEO/COO in the life science industry with 30 years of international experience and achievement in private and Fortune 500 Companies. From innovation to sales, he has a great understanding of the research and medical businesses, supported by a proven record of accomplishments. As the Advisory Board Chair at Parallex BioAssays, he will guide the strategic decisions and participate on short and long-term objectives assessment with a rapid and sustained growth in mind.
Pr. David Juncker
Professor at McGill University, Department of Biomedical Engineering
Pr. Juncker’s interests are in the conception, development and application of novel micro and nanotechnologies for biology and biomedical applications. His research includes the development of scalable antibody microarrays for protein profiling and their use for biomarker discovery and early diagnosis of cancer.
Aerospace Sales Engineer, Trelleborg Sealing Solutions Canada
Serge Giguere, acting member of the Board of Directors brings over 20 years of international business development to Parallex.
There are no current openings, please check back soon.